Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Skin Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1

Interventions

aldesleukin 16Cyclophosphamide 14fludarabine phosphate 11Interleukin-2 11fludarabine 10Nivolumab 7pembrolizumab 5cemiplimab 5Ipilimumab 5Temozolomide 4Fluorouracil 4Aminolevulinic Acid 4sonidegib 3Surgical Procedures, Operative 3Radiotherapy 3zanolimumab 2trametinib 2talabostat 2montanide ISA 51 2dabrafenib 2Whole-Body Irradiation 2Tablets 2Semaxinib 2Radiation 2Petrolatum 2Peptides 2MART-1 Antigen 2Gefitinib 2Eflornithine 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Skin Neoplasms × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00295958 2012-06-14

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
26 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡